Basic information Safety Related Supplier

ChemicalBook Product Catalog FIDAS-5

1/1

FIDAS-5 NEW

$54.00 1mg

$77.00 2mg

$118.00 5mg

Min. Order
Purity99.17%
Cas No1391934-98-7
Supply Ability10g
Update time2026-04-14

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

VIP6Y

United States

United States

show more

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Trade Company

Chemical Properties

Product Name	FIDAS-5
CAS No	1391934-98-7
EC-No
Min. Order
Purity	99.17%
Supply Ability	10g
Release date	2026/04/14

Product Introduction

Bioactivity

Name	FIDAS-5
Description	FIDAS-5 is an orally active methionine adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM. It can effectively compete with S-adenosylmethionine for MAT2A binding and has anticancer effects.
In vitro	METHODS: FIDAS-5 (3 μM; 36 hours) was used to treat LS174T cells, and the levels of S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) were observed. RESULTS FIDAS-5 reduced S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) levels in LS174T cells. METHODS: FIDAS-5 (3 μM; 7 days) was used to treat LS174T cells, and the proliferation of LS174T cells was observed. RESULTS FIDAS-5 significantly inhibited the proliferation of LS174T cells. METHODS: FIDAS-5 (3 μM) treatment inhibited LS174T colorectal cancer cells, and the expression of c-Myc and cyclinD1 in LS174T colorectal cancer cells was observed by westernBlot. RESULTS FIDAS-5 inhibited the expression of c-Myc and cyclinD1 in LS174T colorectal cancer cells [1]. METHODS: OPM2 cells were transduced with siMAT2A or scrambled siRNA for 3 days. MAT2A-silenced and parental OPM2 cells were treated with different doses of FIDAS-5 (0.5, 1, 2 μM) to determine whether FIDAS-5 indeed impairs MM cell survival by inhibiting the enzymatic activity of MAT2A. RESULTS The antitumor effect of FIDAS-5 on MAT2A-silenced cells was impaired compared with cells transduced with scrambled siRNA. FIDAS-5 indeed inhibited MM cell survival in part by targeting MAT2A. [2]
In vivo	METHODS: Tumors were induced in athymic nude mice by subcutaneous injection of HT29 CRC cells. FIDAS-5 treatment (20 mg/kg) was administered orally via gavage. The oral efficacy of FIDAS-5 on HT29 tumor xenografts in nude mice was tested by measuring tumors twice weekly using digital calipers. RESULTS FIDAS-5 significantly inhibited xenograft tumor growth with minimal body weight differences. [1]
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Powder: -20°C for 3 years Shipping with blue ice/Shipping at ambient temperature.
Solubility Information	10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (15.28 mM), Sonication is recommended. DMSO : 125 mg/mL (477.61 mM), Sonication is recommended.
Keywords	SAM \| SAH \| S-adenosylmethionine \| p21WAF1/CIP1 \| Methionine S-adenosyltransferase 2A(MAT2A) \| MAT2A \| Inhibitor \| inhibit \| FIDAS-5 \| FIDAS5 \| FIDAS 5 \| CyclinD1 \| colorectal \| c-Myc \| anti-proliferation \| anti-cancer
Inhibitors Related	MAT2A-IN-9 \| FIDAS-3 \| AG-270 \| AGI-43192 \| MAT2A inhibitor 4 \| MAT2A-IN-11 \| MAT2A inhibitor 2 \| MAT2A inhibitor 5 \| AGI-24512 \| 3-TYP \| AGI-25696 \| PF-9366

show more

Company Profile Introduction

You may like

Recommended supplier

Send Inquriy